2025 Analysis: Opportunities and Risks in the Evolving Anti-Asthmatics And COPD Drugs Market
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What CAGR Is Anticipated for the Anti-Asthmatics And COPD Drugs Market Through 2029?
The market size for anti-asthmatics and copd drugs has seen considerable expansion in recent years. It is projected to increase from $80.85 billion in 2024 to $85.08 billion in 2025, with a compound annual growth rate (CAGR) of 5.2%. Factors driving historical growth include a surge in respiratory diseases, a rise in tobacco smoking, the effects of global warming, an aging population, the growth of emerging markets, advancements in drug discovery methods, and increased spending in healthcare.
The market for anti-asthmatics and COPD drugs is anticipated to witness robust growth in the coming years, reaching “$105.07 billion by 2029 with a CAGR of 5.4%.” Factors contributing to this growth during the forecast period include the rising trend of e-cigarettes/vaping, escalating obesity rates, advancements in technology, a high proportion of undiagnosed individuals, the application of these drugs in the treatment of COVID-19 patients, and an increase in the intake of fats. Future trends in this market encompass the design of probiotic drugs for asthma, the development of anti-il-5 drugs for broadening business scopes, the introduction of innovative products to strengthen market position amidst the fierce competition, higher investments in bioelectric medicines, focus on enhancing collaboration numbers, personalizing treatments, and formulating combination drugs for improved outcomes, and the development of biologics to leverage the growing demand for such products.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3802&type=smp
What Market Forces Are Driving The Anti-Asthmatics And COPD Drugs Sector In 2025 And Beyond?
The market for anti-asthmatics and COPD drugs is heavily influenced by mutable risk factors, such as smoking, a sedentary lifestyle, and a poor nutritional regimen. Despite a worldwide downward trend in smoking, there’s a growing prevalence in developing nations like China, India, Indonesia, and Nigeria. For example, it’s anticipated that tobacco smokers will increase by 24 million in Indonesia and 7 million in Nigeria by 2025, and China accounts for over 40% of the global cigarette use. The risk of Asthma and COPD also rises with the consumption of fats, particularly saturated fatty acids, which is more prevalent in affluent nations such as the USA and Europe. According to the WHO, in these developed countries, more than 35% of the total energy requirement is derived from fats, compared to less than 20% in low-income nations, and under 25% in lower-middle-income countries.
The anti-asthmatics and copd drugs market covered in this report is segmented –
1) By Drug Class: Bronchodilators, Anti-Inflammatory Drugs, Monoclonal Antibodies, Combination Drugs
2) By Distribution Channel: Hospital Pharmacies, General Pharmacies, Online Retailers
3) By End User: Asthma Patients, COPD Patients
4) By Therapy: Preventive, Curative
5) By Route Of Administration: Oral, Inhaled, Intravenous, Subcutaneous
6) By Age Group: Below 5, 5-14, 15-60, Above 60
Subsegments:
1) By Bronchodilators: Short-Acting Beta-Agonists (SABAs), Long-Acting Beta-Agonists (LABAs), Anticholinergics (Short-Acting And Long-Acting), Methylxanthines
2) By Anti-Inflammatory Drugs: Corticosteroids (Inhaled And Systemic), Leukotriene Modifiers, Phosphodiesterase-4 Inhibitors
3) By Monoclonal Antibodies: Anti-IgE Antibodies, Anti-IL-5 Antibodies, Anti-IL-4 Or IL-13 Antibodies
4) By Combination Drugs: Combination Bronchodilator Inhalers (LABA + LAMA), Inhaled Corticosteroid + Long-Acting Beta-Agonist (ICS + LABA)
What Notable Trends Are Shaping The Direction Of The Anti-Asthmatics And COPD Drugs Market?
Big players in the anti-asthmatics and COPD drugs market, are exploring novel developments such as fixed-dose combinations (FDC) of drugs like Indacaterol and Mometasone to enhance market profitability. The medication, dispensed through the Breezhaler device, is designed for daily, continual asthma management. For example, in June 2022, Glenmark Pharmaceuticals, an American pharmaceutical company, introduced a fixed-dose combination (FDC) drug of the same components for the treatment of unmanageable asthma in India. The drug is marketed under the name Indamet and is available in three different formulas, all containing 150 mcg of Indacaterol and variable doses of Mometasone in 80 mcg, 160 mcg, and 320 mcg strengths.
Which Firms Are Considered Leaders In The Anti-Asthmatics And COPD Drugs Market Space?
Major companies operating in the anti-asthmatics and COPD drugs market include GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi S.A., Chiesi Farmaceutici S.p.A., Teva Pharmaceutical Industries Limited, Merck & Co. Inc., Sumitomo Dainippon Pharma Co. Ltd., China National Pharmaceutical Group Co. Ltd. (Sinopharm), Shanghai Acebright Pharmaceuticals Group Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd, Hanmi Pharmaceutical, Cipla Limited, Aurobindo Pharma Limited, KYORIN Holdings Inc., Nichi-Iko Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Daewoong Pharmaceutical Co. Ltd, Shanghai Anovent Pharma, China Meheco Group Co. Ltd., Lupin Limited, ASGEN Pharmaceutical Co. Ltd, Abbott Laboratories, Pfizer, Vectura Group, Bristol Myers Squibb, Apotex Inc., EMS Pharma, Hypermarcas, Ache, Eurofarma, Bayer, Biolab Farmaceuticad, Cristalia, Libbs, Julphar, Neopharma, Adcock Ingram, Aspen Nigeria
What Role Do Regional Policies And Investments Play In Anti-Asthmatics And COPD Drugs Market Expansion?
North America was the largest region in the anti-asthmatics and COPD drugs market in 2024. Middle East is expected to be the fastest-growing region in the global anti-asthmatics and COPD drugs market during the forecast period. The regions covered in the anti-asthmatics and COPD drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=3802&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
